2017 Award Recipient: Michael N. Hall, Ph.D.
When?
Monday, May 1, 2017
6:00 pm
Where?
National Press Club
529 14th Street NW,
Washington, DC 20045
Professor of Biochemistry, Biozentrum of the University of Basel, Switzerland
The 2017 Selection Committee announced cell growth research pioneer Michael N. Hall will receive the 2017 Szent-Györgyi Prize for Progress in Cancer Research.
In 1991, Hall discovered one of the most important cancer cell targets in the modern era of oncology, which he named “Target of Rapamycin” or TOR. He discovered that TOR – a conserved protein kinase – controls cell growth and a wide range of metabolic processes that when dysregulated cause disorders such as cancers, cardiovascular disease, diabetes and obesity. TOR inhibitors are used today in treatments for kidney, breast, brain and pancreatic cancers, and numerous clinical trials are currently underway testing TOR inhibitors in the treatments of many types of cancer.
Featured Items
“I was very impressed by everything I heard. I found the presented research to be of really high quality and very innovative. This is very refreshing, and, in my opinion, sets AIM-HI and NFCR apart in a very good way.” -Isidore Rigoutsos, Ph.D., Director, Center for Computational Medicine, Thomas Jefferson University
Isidore Rigoutsos, Ph.D.“I wish I was younger in my career because the format of the conference of mixing scientists, entrepreneurs, and investors would have really opened my eyes.” -Daniel Johnson, Ph.D., Professor and Vice Chair of Research, Otolaryngology and Head and Neck Surgery, University of California San Francisco
Daniel Johnson, Ph.D.“Let me state right at the beginning that if I don’t attend another great conference for the next few years, I will not mind it because of what I was just given the opportunity to attend. Thank you very much for giving me such a prominent slot in the morning panel among some incredible women in the field. It was a humbling experience to be in the company of so many outstanding and accomplished. Congratulations on organizing a totally mind-blowing NFCR Global Summit and collecting a constellation of shining stars under one roof for several days! Besides the talks and panel discussions, the opportunity to network and exchange ideas with others was deeply appreciated. I also loved the way you mixed hard science, heartbreaking oncology stories, and glamorous dinners.” -Azra Raza, M.D., Chan Soon-Shiong Professor of Medicine, Columbia University in New York
Azra Raza, M.D.“NFCR has assembled key and influential segments of the entire oncology ecosystem at the Global Summit, which is quite unique. It’s a great place to meet up with my trusted peers and get introduced to potential partners. The experience resulted in instructive and fruitful outcomes that have nourished our company and enlightened its future direction." -María Varela, CEO, ARDAN Pharma
María Varela“I want to sincerely thank you for such a well-organized Global Summit of the National Foundation of Cancer Research. The event was so well received by the audience and participants that I want to congratulate you on this achievement. On a more personal note, I very much appreciate all the connections and friendships I have made during the event, both last year and this year. Both my firm, Dorsey & Whitney, and I look forward to continuing to work with you and your organizations at future events."
Catherine X. Pan-Giordano
